Multi-omic Pathway and Network Analysis to Identify Biomarkers for Hepatocellular Carcinoma

The threat of Hepatocellular Carcinoma (HCC) is a growing problem, with incidence rates anticipated to near double over the next two decades. The increasing burden makes discovery of novel diagnostic, prognostic, and therapeutic biomarkers distinguishing HCC from underlying cirrhosis a significant f...

Full description

Saved in:
Bibliographic Details
Published in:2019 41st Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) 2019-07, Vol.2019, p.1350-1354
Main Authors: Barefoot, Megan E., Varghese, Rency S., Zhou, Yuan, Poto, Cristina Di, Ferrarini, Alessia, Ressom, Habtom W.
Format: Article
Language:English
Subjects:
Biochemistry
Cancer
glycoproteomics
HCC
Immune system
Liver
Metabolomics
multi-omic
network and pathway analysis
transcriptomics
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The threat of Hepatocellular Carcinoma (HCC) is a growing problem, with incidence rates anticipated to near double over the next two decades. The increasing burden makes discovery of novel diagnostic, prognostic, and therapeutic biomarkers distinguishing HCC from underlying cirrhosis a significant focus. In this study, we analyzed tissue and serum samples from 40 HCC cases and 25 patients with liver cirrhosis (CIRR) to better understand the mechanistic differences between HCC and CIRR. Through pathway and network analysis, we are able to take a systems biology approach to conduct multi-omic analysis of transcriptomic, glycoproteomic, and metabolomic data acquired through various platforms. As a result, we are able to identify the FXR/RXR Activation pathway as being represented by molecules spanning multiple molecular compartments in these samples. Specifically, serum metabolites deoxycholate and chenodeoxycholic acid and serum glycoproteins C4A/C4B, KNG1, and HPX are biomarker candidates identified from this analysis that are of interest for future targeted studies. These results demonstrate the integrative power of multi-omic analysis to prioritize clinically and biologically relevant biomarker candidates that can increase understanding of molecular mechanisms driving HCC and make an impact in patient care.
ISSN:1558-4615
2694-0604
DOI:10.1109/EMBC.2019.8856576